Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 20 - Any |
| Updated: | 5/12/2018 |
| Start Date: | February 2010 |
| End Date: | November 2014 |
Clinical and Neurophysiological Study of Subthalamic Brain Stimulation in PD
Deep brain stimulation (DBS) improves debilitating symptoms of movement disorders when
conventional medical therapies and novel surgical therapies fail. Despite the remarkable
efficacy of DBS, its therapeutic mechanism remains unclear. There is controversy regarding
whether the therapeutic effects of DBS are associated with inhibition or excitation of target
neurons, the introduction of new activity into the network, or a combination of these
mechanisms. Additionally, it is unclear why stimulus frequency plays an important role in the
clinical response to therapy. The fundamental hypothesis of this proposal is that unilateral
subthalamic nucleus (STN) DBS in PD alters neuronal activity in the bilateral basal
ganglia-thalamic-cortical motor system in a manner that is dependent on stimulation
frequency.
conventional medical therapies and novel surgical therapies fail. Despite the remarkable
efficacy of DBS, its therapeutic mechanism remains unclear. There is controversy regarding
whether the therapeutic effects of DBS are associated with inhibition or excitation of target
neurons, the introduction of new activity into the network, or a combination of these
mechanisms. Additionally, it is unclear why stimulus frequency plays an important role in the
clinical response to therapy. The fundamental hypothesis of this proposal is that unilateral
subthalamic nucleus (STN) DBS in PD alters neuronal activity in the bilateral basal
ganglia-thalamic-cortical motor system in a manner that is dependent on stimulation
frequency.
Inclusion Criteria:
- Patients with Parkinson disease who have undergone subthalamic deep brain stimulation
Exclusion Criteria:
- Patients who are unable to follow verbal instructions
- Patients who are unable to tolerate being off their Parkinson's medications for 12
hours
- Patients who are medically unstable
We found this trial at
1
site
1720 2nd Ave S
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 934-4011
Principal Investigator: Harrison C Walker, MD
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
